KEAP1 mutations lead to constitutively active NRF2, enhanced transcriptional induction of antioxidants, xenobiotic metabolism enzymes, drug efflux pumps, and the subsequent protection of cancer cells against chemotherapeutic drugs [24]. Here, KEAP1 is linked to cancer.